基础医学与临床2024，Vol.44Issue(8)：1088-1093,6.DOI:10.16352/j.issn.1001-6325.2024.08.1088
靶向异常通路的动脉性肺动脉高压新型药物研发
Development of novel therapies targeting at dysregulated signaling pathways in pulmonary arterial hypertension
高艺丹 1蒋雪涵 2张红 2杨沛然2
作者信息
- 1. 内蒙古医科大学 基础医学院,内蒙古呼和浩特 010110||中国医学科学院基础医学研究所 北京协和医学院基础学院 生理学系,北京 100005
- 2. 中国医学科学院基础医学研究所 北京协和医学院基础学院 生理学系,北京 100005
- 折叠
摘要
Abstract
Pulmonary arterial hypertension(PAH)is a complex pulmonary vascular disease characterized by pro-gressive elevation of mean pulmonary artery pressure resulted from the pathological feature of pulmonary vascular re-modeling.Without medical intervention,PAH can eventually lead to right heart failure and death of patients.Up to the present,there are few treatment options for PAH are still mainly function through pulmonary vasodilation.Although these treatments can alleviate symptoms,the prognosis remains poor.In recent years,breakthroughs have been made in understanding the pathogenesis of PAH,thus support the development of new treatment strategies tar-geting at dysregulation of signaling pathways in PAH.This review focuses on five critical pathways and the relevant drugs those entered phase Ⅱ clinical trials and discusses their therapeutic potential,so to provide a basis for future research on targeting therapies for PAH patients.关键词
动脉性肺动脉高压/分子通路/配受体/靶向治疗/药物研发Key words
pulmonary arterial hypertension/molecular pathways/ligands and receptors/targeted therapy/drug development分类
医药卫生引用本文复制引用
高艺丹,蒋雪涵,张红,杨沛然..靶向异常通路的动脉性肺动脉高压新型药物研发[J].基础医学与临床,2024,44(8):1088-1093,6.
